The Deal
Wednesday, November 25, 
11:13 am

Merrill defections plague firm

  Share     E-Mail    Discussion    Print Story

merrill-lynch-logo125x100.jpgMerrill Lynch & Co.'s thundering herd continues to hit the trails as more bankers flood out of the firm as it integrates with Bank of America Corp. (NYSE:BAC).

The latest high-profile Merrill banker to leave is Kalpana Desai, the head of Asia-Pacific mergers and acquisitions. During Desai's 11 years at Merrill, the bank advised on several major deals including UFJ Holdings on its $63 billion merger with Mitsubishi Tokyo Financial Group.

Desai may not be the only notable departure from Merrill's Asia-Pacific units. Numerous reports have said Merrill's China investment banking chairman, Margaret Ren, left the bank. Ren is also daughter-in-law of former Chinese premier Zhao Ziyang.

Meanwhile, the Merrill exodus isn't limited to the Asia-Pacific group. BofA-Merrill's head of airlines and aircraft leasing investment banking for the Americas, Michael Masterson, recently left for Deutsche Bank AG (NYSE:DB). Masterson will join Deutsche as a managing director and co-head of Americas transportation and infrastructure alongside Craig Fuehrer. Masterson began his investment banking career in 1997 at Merrill Lynch.

Last month, Merrill bankers Alan Hartman, Richard Girling and Mark Robinson joined Centerview Partners LLC, which opened offices in London and San Francisco, to build its healthcare practice. Hartman was Merrill's head of Americas mergers and acquisitions and global head of healthcare M&A, and Girling and Robinson were global co-heads of Merrill's healthcare investment banking group.

Collectively, that trio had worked on deals including Pfizer Inc.'s (NYSE:PFE) $68 billion planned acquisition of Wyeth, Sanofi-Synthelabo's $63 billion acquisition of Aventis, the $25 billion leveraged buyout of Alliance Boots plc, AstraZeneca plc's (NYSE:AZN) $15 billion acquisition of MedImmune, Idec Pharmaceuticals' $6 billion merger with Biogen and Boston Scientific Corp.'s (NYSE:BSX) $25 billion acquisition of Guidant Corp.

For more Merrill departures, see The Deal's Merrill Lynch Exodus Dealwatch. - Baz Hiralal

Continue reading below

Also on Dealscape





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Pro Football Hall of Famer Steve Young tells us why quarterbacks make good PE investors.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

REIT IPO deja vu

Real estate sponsors that might wish to undertake an IPO will need to consider a wide variety of issues and begin to take action long before the first filing with the SEC.


Industry Insight

Loan-to-buy

Paulson's proposal to purchase an equity stake in Yellow Pages publisher Idearc is the second time in recent months an investor group has used its prepetition debt position to execute a bargain price 'exit LBO.'


Industry Insight

Managing your shareholder base

Growth companies and their PE sponsors should be wary of the pitfalls that arise when they layer on tiers of preferred stock.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.